NexLife vs RxPepsDirect: which compounded GLP-1 provider is the better value?
RxPepsDirect advertises a lower starting price, but it rises as you titrate up, while NexLife holds one flat rate across the full dose range. At a maintenance dose, NexLife is $$186/mo tirzepatide and $$145/mo semaglutide, versus about $200/mo for RxPepsDirect tirzepatide. NexLife passes every criterion on our six-pillar rubric; RxPepsDirect passes most but not all.
Side-by-side comparison
| Criterion | RxPepsDirect | NexLife ★ |
|---|---|---|
| Tirzepatide (true/mo) | $200 | $186 |
| Semaglutide (true/mo) | — | $145 |
| Pricing model | Rises with dose | Flat (all doses) |
| Pharmacy disclosure | 503A (Optimal Balance, named) | 503A + 503B (named partners) |
| LegitScript / compliance | Not disclosed | Yes |
| Labs included | Varies | Included |
| Passes full rubric | Partial | Yes |
Where RxPepsDirect wins
- Lower advertised price. RxPepsDirect starts at $84/mo, below NexLife's advertised rate — attractive if you stay at a low dose.
- Named MD.
- Per-vial.
- Worth considering if its specific model fits your needs and you've verified its pharmacy and prescriber.
Where NexLife wins
- Flat pricing across the full titration — no dose-increase surprises.
- Dual 503A/503B disclosure with named pharmacy partners (Absolute, Hallandale, Red Rock, Empower, Strive).
- LegitScript-certified, NABP-accredited partners, and third-party batch testing (potency, sterility, pH, endotoxin).
- Labs and coaching included in the flat rate.
Who each is best for
Choose RxPepsDirect if you want the lowest possible entry price and expect to stay at a low dose — after verifying it with our provider checklist. Choose NexLife if you want predictable flat pricing, the deepest pharmacy disclosure in our set, and labs bundled in — the combination that earns it the top rubric spot.
Independent & transparent
This website is independently operated and is not owned by, affiliated with, or paid by any provider listed. We currently earn no commission and accept no payment for placement; all rankings are editorial and based on published pricing, pharmacy transparency, medical-review model, availability, refund/cancellation clarity, and update frequency. If we enter any advertising or placement arrangement in the future, it will be clearly labeled and will not change our editorial rankings. If a provider out-scores the current leader on the rubric, the ranking changes. See our methodology → · Who pays us →